Logo image of CING

CINGULATE INC (CING) Stock Price, Quote, News and Overview

NASDAQ:CING - Nasdaq - US17248W3034 - Common Stock - Currency: USD

4.27  +0.06 (+1.43%)

CING Quote, Performance and Key Statistics

CINGULATE INC

NASDAQ:CING (5/1/2025, 3:51:09 PM)

4.27

+0.06 (+1.43%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High20.83
52 Week Low1.8
Market Cap16.10M
Shares3.77M
Float3.67M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO10-07 2021-10-07


CING short term performance overview.The bars show the price performance of CING in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5

CING long term performance overview.The bars show the price performance of CING in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of CING is 4.27 USD. In the past month the price decreased by -0.94%. In the past year, price decreased by -63.63%.

CINGULATE INC / CING Daily stock chart

CING Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 61.41 756.87B
JNJ JOHNSON & JOHNSON 15.39 372.71B
NVO NOVO-NORDISK A/S-SPONS ADR 19.03 292.22B
NVS NOVARTIS AG-SPONSORED ADR 13.24 220.38B
AZN ASTRAZENECA PLC-SPONS ADR 18.97 218.78B
MRK MERCK & CO. INC. 10.7 209.72B
PFE PFIZER INC 7.48 136.09B
SNY SANOFI-ADR 14.04 132.69B
BMY BRISTOL-MYERS SQUIBB CO 6.77 101.10B
GSK GSK PLC-SPON ADR 7.06 78.71B
ZTS ZOETIS INC 26.39 69.69B
TAK TAKEDA PHARMACEUTIC-SP ADR 32.71 47.35B

About CING

Company Profile

CING logo image Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The company is headquartered in Kansas City, Kansas and currently employs 13 full-time employees. The company went IPO on 2021-10-07. The firm is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The firm is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.

Company Info

CINGULATE INC

1901 W. 47Th Place

Kansas City KANSAS US

Employees: 13

Company Website: https://www.cingulate.com/

Investor Relations: https://www.cingulate.com/investors

Phone: 19139422300

CINGULATE INC / CING FAQ

What is the stock price of CINGULATE INC today?

The current stock price of CING is 4.27 USD. The price increased by 1.43% in the last trading session.


What is the ticker symbol for CINGULATE INC stock?

The exchange symbol of CINGULATE INC is CING and it is listed on the Nasdaq exchange.


On which exchange is CING stock listed?

CING stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CINGULATE INC stock?

10 analysts have analysed CING and the average price target is 33.05 USD. This implies a price increase of 673.96% is expected in the next year compared to the current price of 4.27. Check the CINGULATE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CINGULATE INC worth?

CINGULATE INC (CING) has a market capitalization of 16.10M USD. This makes CING a Nano Cap stock.


How many employees does CINGULATE INC have?

CINGULATE INC (CING) currently has 13 employees.


What are the support and resistance levels for CINGULATE INC (CING) stock?

CINGULATE INC (CING) has a support level at 3.85 and a resistance level at 4.34. Check the full technical report for a detailed analysis of CING support and resistance levels.


Should I buy CINGULATE INC (CING) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CINGULATE INC (CING) stock pay dividends?

CING does not pay a dividend.


What is the Price/Earnings (PE) ratio of CINGULATE INC (CING)?

CINGULATE INC (CING) does not have a PE ratio as the earnings reported over the last twelve months were negative (-16.38).


What is the Short Interest ratio of CINGULATE INC (CING) stock?

The outstanding short interest for CINGULATE INC (CING) is 4.67% of its float. Check the ownership tab for more information on the CING short interest.


CING Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

CING Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to CING. CING may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CING Financial Highlights

Over the last trailing twelve months CING reported a non-GAAP Earnings per Share(EPS) of -16.38. The EPS increased by 71.53% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -104.58%
ROE -208.51%
Debt/Equity 0.67
Chartmill High Growth Momentum
EPS Q2Q%96.69%
Sales Q2Q%N/A
EPS 1Y (TTM)71.53%
Revenue 1Y (TTM)N/A

CING Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to CING. The Buy consensus is the average rating of analysts ratings from 10 analysts.


Ownership
Inst Owners2.84%
Ins Owners0.13%
Short Float %4.67%
Short Ratio1.86
Analysts
Analysts82
Price Target33.05 (674%)
EPS Next Y75.86%
Revenue Next YearN/A